[go: up one dir, main page]

MX2009009355A - Compuesto de bencimidazol y uso farmaceutico del mismo. - Google Patents

Compuesto de bencimidazol y uso farmaceutico del mismo.

Info

Publication number
MX2009009355A
MX2009009355A MX2009009355A MX2009009355A MX2009009355A MX 2009009355 A MX2009009355 A MX 2009009355A MX 2009009355 A MX2009009355 A MX 2009009355A MX 2009009355 A MX2009009355 A MX 2009009355A MX 2009009355 A MX2009009355 A MX 2009009355A
Authority
MX
Mexico
Prior art keywords
pharmaceutical use
benzimidazole compound
orl
receptor agonist
disclosed
Prior art date
Application number
MX2009009355A
Other languages
English (en)
Inventor
Hideki Horiuchi
Tokushi Hanano
Masanori Minoguchi
Koji Teshima
Masakazu Nakano
Shin-Ichiro Ono
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2009009355A publication Critical patent/MX2009009355A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un agonista del receptor de ORL-1 que tiene biodisponibilidad mejorada, basada en una estabilidad metabólica superior y fuerte y alta selectividad, en comparación con los compuestos convencionales; un compuesto representado por la fórmula (I) (ver fórmula (I)) en donde cada símbolo es como se definió en las reivindicaciones.
MX2009009355A 2007-03-01 2008-02-28 Compuesto de bencimidazol y uso farmaceutico del mismo. MX2009009355A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2007051842 2007-03-01
JP2007059260 2007-03-08
JP2007078845 2007-03-26
JP2007093846 2007-03-30
PCT/JP2008/053524 WO2008105497A1 (ja) 2007-03-01 2008-02-28 ベンゾイミダゾール化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
MX2009009355A true MX2009009355A (es) 2009-09-11

Family

ID=39721321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009355A MX2009009355A (es) 2007-03-01 2008-02-28 Compuesto de bencimidazol y uso farmaceutico del mismo.

Country Status (11)

Country Link
US (1) US8877779B2 (es)
EP (1) EP2128154B1 (es)
JP (2) JP5313865B2 (es)
KR (1) KR101165504B1 (es)
CN (1) CN101622241B (es)
AU (1) AU2008219980B2 (es)
BR (1) BRPI0808025A2 (es)
CA (1) CA2679530C (es)
ES (1) ES2541133T3 (es)
MX (1) MX2009009355A (es)
WO (1) WO2008105497A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120102172A (ko) 2007-08-31 2012-09-17 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
BRPI0911031B8 (pt) 2008-07-21 2021-05-25 Purdue Pharma Lp compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
TW201016675A (en) 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
EP2394997A4 (en) * 2009-02-03 2012-07-18 Mitsubishi Tanabe Pharma Corp PROCESS FOR PREPARING 1- (4-PIPERIDINYL) BENZIMIDAZOLONE DERIVATIVES
WO2014153529A1 (en) 2013-03-22 2014-09-25 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
JP6146164B2 (ja) * 2013-06-28 2017-06-14 三菱瓦斯化学株式会社 テトラリン骨格を有する新規アルデヒド、およびその製造方法。
TWI685497B (zh) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
SI3365346T1 (sl) 2015-10-23 2020-04-30 Esteve Pharmaceuticals, S.A. Spojine oksa diazaspiro s protibolečinskim delovanjem
HUE060275T2 (hu) 2015-11-16 2023-02-28 Esteve Pharmaceuticals Sa Hatóanyaggal való visszaélés és addikció kezelésére alkalmas oxadiazaspiro-vegyületek
MX2019006084A (es) * 2016-11-28 2019-11-12 Mitsubishi Tanabe Pharma Corp Farmaco para tratar la adiccion a la cocaina o prevenir la recurrencia de la misma.
SI3697795T1 (sl) 2017-10-17 2024-05-31 Acondicionamiento Tarrasense Soli (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oksa-4,9-diazaspiro(5.5) undekan-3-ona
KR20240022630A (ko) * 2021-07-14 2024-02-20 이창 휴먼웰 파마슈티칼 코포레이션, 리미티드 피페리딘 유도체 및 그 약물 조성물, 제조 방법과 용도
WO2025146193A1 (zh) * 2024-01-05 2025-07-10 宜昌人福药业有限责任公司 一种环己基取代哌啶衍生物、包含其的药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226058C (en) 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
EP0990653B1 (en) 1997-05-30 2004-09-15 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
PT921125E (pt) 1997-12-05 2002-06-28 Hoffmann La Roche Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
JP3342478B2 (ja) 1998-01-19 2002-11-11 ファイザー製薬株式会社 Ｏｒｌ１−レセプターアゴニストとしての４−（２−ケト−１−ベンズイミダゾリニル）ピペリジン化合物
ES2194402T3 (es) 1998-06-12 2003-11-16 Hoffmann La Roche Derivados de di - o triaza-espiro(4,5)decano..
DE69902606T2 (de) 1998-06-12 2003-04-24 F. Hoffmann-La Roche Ag, Basel Spiro(piperidin-4,1'-pyrrolo(3,4-c)pyrrole)
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
AU8657398A (en) 1998-07-30 2000-02-21 Picower Institute For Medical Research, The Immunotherapeutic anti-cancer pharmaceutical compositions
US7456198B2 (en) 1999-12-06 2008-11-25 Purdue Pharma L.P. Benzimidazole compounds having nociceptin receptor affinity
ES2323876T3 (es) * 2001-04-18 2009-07-27 Euro-Celtique S.A. Derivados de 1-(4-piperidinil)-1,3-dihidro-2h-benzoxazol-2-ona y compuestos relacionados como analogos de la nociceptina y ligandos de orl1 para el tratamiento del dolor.
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US20030226657A1 (en) * 2002-04-01 2003-12-11 Wallace Thomas E. Food delivery system and method for storing and heating food to a serving temperature
US8067603B2 (en) 2003-09-25 2011-11-29 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
CN1856485A (zh) * 2003-09-25 2006-11-01 索尔瓦药物有限公司 作为人orl1受体激动剂的苯并咪唑酮和喹唑啉酮衍生物
DE102004030290A1 (de) 2004-06-23 2006-01-19 Siemens Ag Aufbau einer Verbindung für den Austausch von Daten eines IP-basierten Dienstes
JP4122015B2 (ja) 2005-08-19 2008-07-23 株式会社日本水処理技研 プラント洗浄方法，アスベスト除去方法および解体処理方法
JP2007059260A (ja) 2005-08-25 2007-03-08 Toshiba Lighting & Technology Corp 照明装置及び照明器具
JP4551848B2 (ja) 2005-09-12 2010-09-29 シャープ株式会社 現像装置およびそれを備える画像形成装置
JP2007093846A (ja) 2005-09-28 2007-04-12 Sanyo Epson Imaging Devices Corp 電気光学装置、および電子機器

Also Published As

Publication number Publication date
EP2128154B1 (en) 2015-04-08
JPWO2008105497A1 (ja) 2010-06-03
BRPI0808025A2 (pt) 2014-06-24
EP2128154A1 (en) 2009-12-02
KR101165504B1 (ko) 2012-07-13
AU2008219980A1 (en) 2008-09-04
US20100120841A1 (en) 2010-05-13
CN101622241B (zh) 2013-05-22
AU2008219980B2 (en) 2012-01-12
CN101622241A (zh) 2010-01-06
WO2008105497A1 (ja) 2008-09-04
JP2013107910A (ja) 2013-06-06
ES2541133T3 (es) 2015-07-16
US8877779B2 (en) 2014-11-04
JP5313865B2 (ja) 2013-10-09
CA2679530C (en) 2012-09-25
KR20090115976A (ko) 2009-11-10
CA2679530A1 (en) 2008-09-04
EP2128154A4 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
MX2009009355A (es) Compuesto de bencimidazol y uso farmaceutico del mismo.
TN2010000148A1 (en) Amide compound
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
MY156319A (en) Spiroheterocyclic n-oxypiperidines as pesticides
WO2008101187A3 (en) Pro-drugs of peripheral phenolic opioid antagonists
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
WO2008153154A1 (ja) 環状化合物、フォトレジスト基材及びフォトレジスト組成物
SG162671A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
EA201170132A1 (ru) 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов
MY161132A (en) Novel herbicides
WO2008151828A8 (en) Novel microbiocides
GEP20125512B (en) Process for synthesis of agomelatin
MX2011007932A (es) Herbicidas nuevos.
WO2013086496A3 (en) 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
SG158026A1 (en) New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2- one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2009127718A3 (en) Novel microbiocides
WO2009156724A3 (en) Pyrido-indole-carboxylic acid compounds
MY178583A (en) Hydantoin derivative
MX2012007385A (es) Derivados de aminoalquilpirimidina como anatagonistas del receptor h4 de histamina.
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
MY159701A (en) New process for the synthesis of (2e)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
TW200643019A (en) Optically active tetrahydronaphthalene derivative
EA200970692A1 (ru) Способы улучшения стабильности стероидных производных

Legal Events

Date Code Title Description
FA Abandonment or withdrawal